# Septal Preparation for TAVR Using Radiofrequency Catheters in Patients With LVOT Obstruction: 1-Year Follow-Up

**Authors:** Bruno P. Valdigem, Antonio Tito Paladino Filho, Andrea de Andrade Vilela, Edileide de Barros Correia, Auristela Ramos, Jorge Eduardo Assef, Dimytri Siqueira, Ibraim Masciarelli Pinto Filho

PMC · DOI: 10.1016/j.jaccas.2025.103606 · JACC Case Reports · 2025-06-11

## TL;DR

This paper discusses using radiofrequency ablation to prepare the heart before a TAVR procedure in patients with LVOT obstruction, showing promising results.

## Contribution

The study presents the longest series of septal ablation before TAVR in patients with intraventricular LVOT obstruction.

## Key findings

- ERASH successfully reduced LVOT gradient before TAVR implantation.
- No patients required pacemaker or ICD implantation.
- The procedure was performed with waiting intervals ranging from 15 days to 3 months.

## Abstract

Left ventricular outflow tract (LVOT) obstruction is frequent in hypertrophic cardiomyopathy. Septal radiofrequency ablation for treatment of LVOT obstruction, which is endocardial radiofrequency ablation of septal hypertrophy (ERASH), was previously performed in patients refractory to medical treatment with catheters used for cardiac arrhythmia ablation. Obstruction of the LVOT during transcatheter aortic valve replacement (TAVR) procedures may lead to suicide ventricle, the dire event of a sudden increase in the intraventricular gradient after valve obstruction alleviation. We present a 2-step procedure for septal preparation before TAVR in a series of 4 cases. All patients underwent ERASH before TAVR, which successfully reduced the LVOT gradient before implant (the longest waiting interval between procedures was 3 months and the shortest was 15 days). No patient underwent pacemaker or implantable cardioverter-defibrillator implant. To the best of our knowledge, this is the longest series of septal ablation before TAVR in patients who also presented with intraventricular LVOT obstruction.

## Linked entities

- **Diseases:** hypertrophic cardiomyopathy (MONDO:0005045)

## Full-text entities

- **Diseases:** LVOT Obstruction (MESH:D000092242), cardiac arrhythmia (MESH:D001145), valve obstruction (MESH:D006349), hypertrophic cardiomyopathy (MESH:D002312), septal hypertrophy (MESH:D006984)
- **Chemicals:** implantable (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12237727/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12237727/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12237727/full.md

---
Source: https://tomesphere.com/paper/PMC12237727